Graves Disease Clinical Trials

15 studies are recruiting for graves disease in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye Disease

   The primary objective of study is to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ETHY-001 in healthy volunteers and participants with Thyroid Eye Disease after single subcutaneous doses.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Site 101, Las Vegas, Nevada

   Run by

   Ethyreal Bio, Inc.

   See if you can join NCT07885605 on ClinicalTrials.gov

2. Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease

   The purpose of this study is to evaluate the efficacy and safety of BHV-1300 in adult participants with Graves' disease who are actively hyperthyroid

   Stage

   Phase 3

   Ages

   18 to 70

   Site

   Site-044, Tucson, Arizona

   Locations

   56 in total

   Run by

   Biohaven Therapeutics Ltd.

   See if you can join NCT07661056 on ClinicalTrials.gov

3. A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease

   The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is distributed and eliminated in the body, how it changes antibody …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Diabetes Associates Medical Group, Orange, California

   Locations

   32 in total

   Run by

   argenx

   See if you can join NCT07570316 on ClinicalTrials.gov

4. A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old

   In this study, researchers will learn more about the use of felzartamab in participants with Graves' Disease, also known as GD. GD is an autoimmune disease, which means the body's immune system attacks its own healthy cells. In people with GD, the immune system produces abnormal antibodies, called …

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Sun City Clinical Research, Glendale, Arizona

   Locations

   11 in total

   Run by

   Biogen

   See if you can join NCT07722546 on ClinicalTrials.gov

5. Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease

   This study is being conducted to look at the effect YB-101 has on thyroid function. This study will also evaluate how safe and well tolerated YB-101 is and how it is distributed through the body. The study consists of a part 1, blinded treatment period, and a part 2 double-blinded treatment period.…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Site 112, Gilbert, Arizona

   Locations

   29 in total

   Run by

   Yarrow Bioscience, Inc.

   See if you can join NCT07682896 on ClinicalTrials.gov

6. NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease

   The purpose of this study is to evaluate how well MER511 is tolerated and what side effects may occur in adults who have Graves' disease. The study drug will be administered either intravenously (into a vein in the arm) or subcutaneously (under the skin). Blood tests will be performed to investigat…

   Stage

   Phase 1

   Ages

   18 to 65

   Site

   Site # 1111, Torrance, California

   Locations

   16 in total

   Run by

   Merida Biosciences

   See if you can join NCT07305818 on ClinicalTrials.gov

7. A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

   This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment. The primary objective of this study is to evaluate the efficacy of IMVT-1402 versus placebo as assessed by T3 …

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Site Number - 1036, Phoenix, Arizona

   Locations

   134 in total

   Run by

   Immunovant Sciences GmbH

   See if you can join NCT06727604 on ClinicalTrials.gov

8. A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

   This is a multi-center, global, randomized, double-blind, placebo-controlled Phase 2b study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Site Number - 1015, Tucson, Arizona

   Locations

   163 in total

   Run by

   Immunovant Sciences GmbH

   See if you can join NCT07018323 on ClinicalTrials.gov

9. Preoperative Corticosteroids in Autoimmune Thyroid Disease

   This study proposes to randomize patients about to undergo surgery for their autoimmune, inflammatory thyroid disease, and determine if a short course of corticosteroids decreases the inflammation of the gland and makes surgery less difficult.

   Stage

   Phase 4

   Ages

   18 and older

   Site

   IU Health North Hospital, Indianapolis, Indiana

   Locations

   3 in total

   Run by

   Indiana University

   See if you can join NCT05435547 on ClinicalTrials.gov

10. Study of BHV-1300 in Graves' Disease

    The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.

    Stage

    Phase 1

    Ages

    18 to 65

    Site

    Site-103, South Gate, California

    Locations

    18 in total

    Run by

    Biohaven Therapeutics Ltd.

    See if you can join NCT06980649 on ClinicalTrials.gov

11. Telehealth Music Therapy for Adults With Endocrine Disorder and Depression

    The goal of this clinical trial is to explore if a telehealth music therapy intervention helps with quality of life, depression symptoms, anxiety symptoms. It will also explore the participants' relationship to music. The main questions it aims to answer are: * Refine and tailor the music therapy i…

    Stage

    Not phased

    Ages

    18 to 65

    Site

    Appalachian State University, Boone, North Carolina

    Run by

    Appalachian State University

    See if you can join NCT07413874 on ClinicalTrials.gov

12. Evaluating an AI Tool for Detecting Thyrotoxic States

    This observational study aims to evaluate the performance of a software-based medical device, Glandy HYPER, in detecting the thyrotoxic state in patients with hyperthyroidism. The device utilizes heart rate data collected from commercially available wearable devices and compares it with thyroid fun…

    Stage

    Not phased

    Ages

    22 and older

    Site

    Umesh Masharani, San Francisco, California

    Run by

    THYROSCOPE INC.

    See if you can join NCT07017907 on ClinicalTrials.gov

13. Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease

    The goal of this randomized pilot feasibility clinical trial is to determine the feasibility of implementing a protocol for a larger trial to assess the effects of high-dose vitamin D supplementation in pediatric patients (9-17 years old) newly diagnosed with Graves' disease. The main questions it …

    Stage

    Phase 2

    Ages

    9 to 17

    Site

    Pediatric Endocrinology at Northwell Health, New Hyde Park, New York

    Run by

    Northwell Health

    See if you can join NCT07369063 on ClinicalTrials.gov

14. Personalized Treatment in Thyroid Disorders

    The Collar Therapy Indicator (CoTI) (A device that is placed in collar around the neck resembling a turtle neck sweater collar with a wire and recording box) has been shown in a single small previously published experience to provide data regarding radioiodine exposure that correlates with conventi…

    Stage

    Not phased

    Ages

    21 to 65

    Site

    Johns Hopkins Hospital, Baltimore, Maryland

    Run by

    Johns Hopkins University

    See if you can join NCT03517579 on ClinicalTrials.gov

15. The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction

    This protocol studies the clinical outcome of patients with active thyroid disease with visually significant signs and symptoms of proptosis, pain, diplopiam lid/orbital edema, or lid/orbital erythema recommended for treatment with teprotumumab infusion (Tepezza®). Patients recommended for treatmen…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Walter Reed National Military Medical Center, Bethesda, Maryland

    Run by

    Walter Reed National Military Medical Center

    See if you can join NCT06275373 on ClinicalTrials.gov